Filgrastim Market

Filgrastim Market Analysis

The Filgrastim Market size is estimated at USD 2.23 billion in 2025, and is expected to reach USD 2.70 billion by 2030, at a CAGR of 3.86% during the forecast period (2025-2030).

Filgrastim is commonly prescribed to cancer patients undergoing chemotherapy. Chemotherapy often suppresses the bone marrow's ability to produce enough white blood cells, leaving patients vulnerable to infections. The market for filgrastim is driven by the increasing prevalence of cancer, rising awareness about supportive care measures, and an expanding number of product approvals of both as mono or in combination.

The growing burden of cancer cases increases the need for filgrastim to produce enough white blood cells in those patients. For instance, according to data published by the International Agency for Research on Cancer (IARC) in February 2024, there were an estimated 20 million new cancer cases globally in 2022, which is estimated to be over 35 million new cancer cases by 2050. As per the same source, the three major cancer types reported globally in 2022 included lung, breast, and colorectal cancers. This shows the growing burden of cancer cases globally, which is expected to raise the need for filgrastim treatment, thereby boosting the market’s growth over the forecast period.

The strategies adopted by new market players, such as collaborations and agreements, increase the availability of the products in various countries, driving the market’s growth over the forecast period. For instance, in May 2022, Amgen purchased from Roche the assets and business related to filgrastim and pegfilgrastim in the European Union, Switzerland, and Norway. However, Roche continues as the licensee for filgrastim in the rest of the Middle East, Africa, Asia, and Latin America. With these collaborations, the products can be distributed globally, which is expected to increase filgrastim's availability globally and boost market growth over the forecast period.

Therefore, the growing burden of cancer cases and market player strategies are expected to drive market growth over the forecast period. However, the side effects and adverse effects of filgrastim treatment reduce the usage of these products, which is expected to hinder the market's growth over the forecast period.

Filgrastim Market Trends

The Biosimilar Segment is Expected to Hold a Major Market Share Over the Forecast Period

Biosimilar filgrastim closely resembles the approved biologic drug filgrastim. It was developed to compare quality, safety, and efficacy to the original filgrastim. It undergoes rigorous testing before being approved for use to ensure it meets these standards. The biosimilar filgrastim segment is expected to grow significantly over the forecast period owing to the drug's affordable cost, increasing burden of cancer cases, and growing public awareness of biosimilar drugs.

The growing initiatives by various market players to increase the usage of biosimilars globally are likely to raise the demand for biosimilar filgrastim over the coming years. For instance, in May 2022, Sandoz initiated Act4Biosimilars, a global campaign to boost biosimilar adoption rates by a minimum of 30% across over 30 countries by 2030. Act4Biosimilars aims to enhance patient access to advanced medicines by improving the approvability, accessibility, acceptability, and affordability (the 4 A’s) of biosimilars. Hence, the growing awareness among the public about biosimilars with these initiatives will likely boost the segment’s growth over the forecast period.

Furthermore, new product launches increase the widespread availability of biosimilar filgrastim products to the public, which is expected to boost the segment's growth over the forecast period. For instance, in November 2022, Amneal Pharmaceuticals Inc. launched RELEUKO (filgrastim-ayow), a biosimilar to Neupogen, in the United States. This offering targets the treatment of chemotherapy-induced neutropenia.

Therefore, the factors mentioned above, such as growing awareness of biosimilar usage and new product launches, are expected to propel the segment's growth over the forecast period.

North America is Expected to Hold a Significant Share of the Market Over the Forecast Period

North America is expected to hold a significant market share due to the higher prevalence of cancer and HIV infections, advancements in medical technology, which are leading to better and more efficient filgrastim products, and growing awareness of the usage of biosimilar drugs in the region.

The growing burden of cancers in the United States is expected to increase the treatment using various chemotherapy drugs, leading to neutropenia, which can be managed using filgrastim. For instance, according to the data published by the National Cancer Institute in May 2024, approximately 2.0 million new cancer cases are expected to be diagnosed in the United States in 2024, compared to 1.95 million in 2023. This shows the growing burden of cancer in the country, which is expected to drive market growth over the forecast period.

Pharmaceutical and biopharmaceutical companies' growing initiatives to raise awareness about biosimilar usage in the country are expected to drive market growth. For instance, in November 2022, the Biosimilars Council of the Association for Accessible Medicines and other members of the International Generic and Biosimilar Medicines Association (IGBA) expressed their commitment to raising awareness about biosimilars. This awareness is expected to increase the usage of affordable biosimilar filgrastim products, boosting the market’s growth in the region over the forecast period.

Moreover, the market players are adopting strategic activities such as partnerships and agreements to expand the availability of these drugs. For instance, in May 2023, Tanvex BioPharma Inc. entered into a distribution agreement with Sandoz AG for Nypozi (filgrastim) in Canada. This ensured widespread availability of filgrastim products in the region, which is expected to boost the market’s growth over the forecast period. Therefore, with the high burden of cancers, growing awareness, and company activities, the market is expected to grow significantly in the region over the forecast period.

Filgrastim Industry Overview

The filgrastim market is fragmented due to the presence of several large and small filgrastim manufacturing companies, especially in developing countries. In addition, the companies often engage in various strategic activities such as developing new formulations, market expansion, and support programs to gain a competitive edge. By engaging in these strategic activities, companies in the filgrastim market can navigate the competitive landscape, address market needs, and capitalize on opportunities for growth and differentiation. Some of the key players in the filgrastim market are Teva Pharmaceutical Industries Ltd (Cephalon Inc.), Amgen Inc., Pfizer Inc., Amneal Pharmaceuticals LLC., and Sandoz Group AG.

Filgrastim Market Leaders

Filgrastim Market News

• June 2024: Tanvex BioPharma Inc. secured FDA approval for its biologics license application for NYPOZI (filgrastim-txid), a biosimilar that references NEUPOGEN (filgrastim). NYPOZI aims to reduce the risk of infections, specifically febrile neutropenia, in patients undergoing treatment for non-myeloid malignancies. These patients are receiving myelosuppressive anticancer drugs known to significantly increase the risk of severe neutropenia accompanied by fever.
• January 2024: Sandoz launched its biosimilar Nypozi (filgrastim) in Canada. Nypozi, a short-acting molecule, is a counterpart to Ziextenzo (pegfilgrastim), a long-acting medication designed to lower the incidence of infections, particularly febrile neutropenia, in patients undergoing chemotherapy.